Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an immunoglobulin presented as a intravenous solution for intravenous use. It replaces deficient antibodies and is used in primary immunodeficiency disorders and certain immune‑mediated conditions in both children and adults.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Panzyga is an immunoglobulin therapy indicated for disorders that involve antibody deficiency or dysregulation: - Primary immunodeficiency diseases (PID): provides supplemental immunoglobulin to reduce infection frequency. - Chronic inflammatory demyelinating polyneuropathy (CIDP): helps maintain functional ability and may reduce relapse risk. - Multifocal motor neuropathy (MMN): offers symptomatic improvement and supports motor function. - Immune thrombocytopenia (ITP) refractory to first‑line therapy: increases platelet counts in selected patients. - Kawasaki disease with coronary artery involvement: supplies passive immunity that may modulate vascular inflammation.

Panzyga, like other intravenous immunoglobulin products, may be associated with a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Fever or chills: typically occurring during or shortly after infusion. - Nausea or vomiting: usually mild and self‑limiting. - Fatigue or malaise: resolves within hours to a day. - Injection site reactions: erythema, warmth or swelling at the infusion site. - Hypertension or transient blood pressure changes.

Serious or Rare Side Effects: - Thromboembolic events: including deep‑vein thrombosis or pulmonary embolism. - Renal impairment: acute kidney injury, particularly with high‑dose regimens. - Aseptic meningitis: severe headache with meningeal signs. - Hemolytic anemia: due to anti‑red‑cell antibodies. - Anaphylaxis or severe hypersensitivity reactions. - Transfusion‑related acute lung injury (TRALI).

When using Panzyga, clinicians should consider several safety measures: - Assess renal function: evaluate baseline creatinine and monitor during therapy. - Screen for thrombotic risk: review patient history of clotting disorders. - Monitor blood pressure: observe for hypertension during infusion. - Evaluate for IgA deficiency: patients with anti‑IgA antibodies may be at higher risk of anaphylaxis. - Adjust infusion rate: slower rates can reduce incidence of headache and chills. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other medicines, requiring attention to dosing and monitoring:

Major Interactions (Avoid): - Live vaccines: concurrent administration can diminish vaccine efficacy and increase adverse event risk. - High‑dose aspirin or NSAIDs: may increase bleeding tendency when combined with immunoglobulin.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, DOACs): immunoglobulin can affect coagulation parameters; monitor INR or relevant labs. - Diuretics: potential for volume overload; assess fluid status. - Immunosuppressants (e.g., rituximab, cyclophosphamide): may alter infection risk profile. - ACE inhibitors: monitor for hypotension during infusion. - Corticosteroids: may mask early signs of infection; observe closely.